Study To Isolate Circulating Tumor Cells From Blood

Armen Hareyan's picture
Advertisement

Tumor Cells From Blood

Biocept is initiating a collaborative study with the University of Texas M.D. Anderson Cancer Center to investigate the ability to isolate circulating tumor cells (CTCs) in blood. The study will use Biocept's proprietary CEE(TM) (Cell Enrichment and Extraction) technology, designed to capture rare cells from a larger heterogeneous cell population. The focus of this study is ovarian cancer.

Advertisement

"This innovation in rare cell capture offers an enhanced opportunity to detect circulating ovarian cancer cells," says principal investigator Anil Sood, MD. "The goal is to provide more powerful tools to monitor the response to treatment, improve early detection and personalize prognosis for our patients."

The study has three goals: to optimize detection and isolation of circulating tumor cells (CTCs) in ovarian cancer patients, to quantify the levels of CTCs in patients with primary or recurrent ovarian cancer, and to compare gene profiles between CTCs and primary tumor specimens. The findings could provide valuable insight towards treatment planning and identification of novel biologic targets.

"We hope that our ability to isolate and quantify circulating tumor cells will improve cancer detection and treatment by giving physicians valuable information early in the disease course," says Gordon Janko, president and CEO of Biocept.

Advertisement